

Irritable Bowel Syndrome: A Post-infectious Syndrome

Juliet Sio Aguilar, M.D., M.Sc.
Professor and Chair of Pediatrics
University of the Philippines

College of Medicine–Philippine General Hospital



DISCLOSURE: Conflicts of Interest

- None




IBS, a Post-infectious Syndrome

- Perspectives Setting: FGIDs
- Pathophysiology of IBS
- Epidemiology of IBS and PI-IBS
- Risk Factors for PI-IBS
- Clinical Manifestations
- Diagnostic Approach
- Management Strategies



Irritable Bowel Syndrome (H2b)

- Rome IV Functional GI Disorders




Age at Presentation

Legend: FD – Functional Dyspepsia

IBS – Irritable Bowel Syndrome



IBS Pathophysiology: Disorder of Brain-Gut Axis



Pediatric IBS: Epidemiology

- Data from meta-analysis
 - Affects 8.8% (6–12%) of population worldwide
- Philippine data:
 - 2.7% of 779 subjects (Rome III criteria)
 - 5.6% of 2,146 subjects (Rome II criteria)



Korterink JJ, et al. PLOS ONE 2015; 10(5): e0126982.doi:10.1371.

Tan M. Pediatric Functional GI Disorders: A Filipino Translated Questionnaire Based on Rome III Criteria. 2011.

Gatcheco FN. Epidemiology of dyspepsia, IBS and FAP among Filipino children. J Pediatr Gastroenterol Nutr 2004; 39: P0838.



Post-infectious IBS (PI-IBS): Epidemiology

- Prevalence

- 14.7% of pediatric patients with infectious enteritis (IE)*
- 11.1% of adult patients with IE*

*significant heterogeneity
[I²=79% (P) and I²=98% (A)]

- Relative Risk of PI-IBS

- 4.1 times higher compared to age- and sex-matched controls (pediatric cases)
 - 95% CI: 2.05,8.15;
I²=0
- 3.8 times higher (overall) compared to age- and sex-matched controls



PI-IBS: Risk Factors

- Infectious enteritis
 - Bacteria (*C. jejuni*, *Salmonella enterica*, *Shigella sonnei*, *E. coli* O157:H7)
 - Virus (norovirus)
 - Protozoa (*G. lamblia*)
- Age: younger
- Gender
- Bloody stools
- Prolonged diarrhea

Thabane M, et al. *Am J Gastroenterol* 2009; 104: 2267–74; Thabane M, et al. *Aliment Pharmacol Ther* 2007; 26: 535–44; Marshak JK, Thabane M, et al. *Gastroenterology* 2006; 131: 445–50.



PI-IBS: Risk Factors

- Infectious enteritis (IE)
 - **Viral IE rates**
 - Within 12 mos of IE (Prevalence = **19.4**; 95% CI: 13.2–27.7)
 - > 12 mos of occurrence (Prevalence = **4.4**; 95% CI: 0.3–39.9)
 - **Protozoal/parasitic rates**
 - Stable over time
 - **Bacterial IE rates**
 - RR = **4.2** (within 12 mos) vs. 2.2 (> 12 mos); p=0.01)
- Gender
 - **Female:**
 - OR = 2.19; 95% CI: 1.57–3.07; I²=72%
- **Abdominal pain**
 - OR = **3.26**; 95% CI: 1.3–8.14; I²=86%
- **Prolonged diarrhea (>7 days)**
 - OR = **2.62**; 95% CI: 1.48–4.61; I²=86%
- **Bloody diarrhea**
 - OR = **1.86**; 95% CI: 1.14–3.03; I²=65%
- **Antibiotic intake**
 - OR = **1.69**; 95% CI: 1.20–2.37; I²=32%



IBS: Clinical Manifestations

- Abdominal pain at least 4 days per month for at least 2 months associated with erratic bowel habit or variable changes in stool form and frequency
 - Pain unresolved with resolution of constipation
 - Symptoms not fully explained by another medical condition





Di Lorenzo C, Nurko S, et al. (eds). Rome IV Pediatric Functional GI Disorders: Disorders of Gut-Brain Interaction. 1st ed. Raleigh, NC: The Rome Foundation. 2016.

Spiller R. *F1000* Research 2016; 5(F1000 Faculty Rev); 780.

Chey WD, et al. JAMA 2015; 313: 949–58.



IBS Subtypes (by Stool Form)



Post-infectious IBS: Prevalence of Subtypes

- IBS-M (most common)
 - **46%**; 95% CI: 31–62%
- IBS-D
 - **40%**; 95% CI: 25–57%
- IBS-C
 - **15%**; 95% CI: 10–21%



Diagnostic Approach in IBS

- History
 - Dietary, family, social, educational history
 - Other historical cues
 - Endemicity of infections/parasitic infestations
 - Malabsorption syndromes (CHO)
- Physical examination
 - Based on the Rome IV criteria and subtype classification using Bristol Stool Form Scale
 - Focus on growth and development
 - Look for alarm signals



Alarm Signals in Pediatric Chronic Abdominal Pain

- Unexplained fever
- Persistent vomiting
- Dysphagia, odynophagia
- Persistent RUQ or RLQ pain
- GI bleeding
- Nocturnal diarrhea
- Poor growth and development
 - Involuntary weight loss
 - Deceleration of linear growth
 - Delayed puberty
- Family history of IBD and peptic ulcer disease
- Arthritis



Diagnostic Approach in IBS

- Basic diagnostics
 - CBC, liver and renal function test
 - Inflammatory markers
 - Amylase, lipase (as indicated)
 - Stool culture and reducing sugars (diarrhea)
- Special investigations
 - Abdominal ultrasound
 - GI endoscopy
 - MRI abdomen
 - Fecal calprotectin
 - May help differentiate IBS from IBD
 - Values < 50 mg/g stool less likely to be IBD



Management in Pediatric IBS

- Few double-blind, randomized trials
- No universally proven therapy



Management Strategies

- Dietary interventions
 - Fiber supplements
 - Lactose-free diet
 - Low fermentable oligo-, di-, monosaccharides and polyols (FODMAP) diet
 - Partially hydrolyzed guar gum
 - Probiotics (LGG, multi-strain VSL#3)
 - Inhibition of pathogen binding; modulation of gut inflammation; reduction in visceral hypersensitivity)




Management Strategies

- Pharmacologic treatment
 - Peppermint oil (antispasmodic, anti-flatulent)
 - Antispasmodics
 - Antibiotics
- Biopsychotherapy
 - Cognitive behavioral therapy
 - Hypnotherapy, yoga, acupuncture



Do Children Grow Out of IBS?



Distribution of IBS subtypes at diagnosis and after 24 months of follow-up (83 children, aged 4–16.6 yrs, Naples, Italy)



Summary Points: PI-IBS

- Recognition of infectious enteritis as a cause of Functional GI Disorder (IBS)
 - Usually presenting as abdominal pain and erratic bowel frequency and consistency
- Risk factors for IBS
 - Related to the etiologic agent, gender, clinical presentation (abdominal pain, prolonged and bloody diarrhea)
 - Increased with antibiotic intake
- Treatment
 - Mainly supportive

